Summary of Key Points Core Viewpoint - On May 23, 2025, Zhaoyan New Drug (603127) closed at 17.3 yuan, marking a 2.73% increase with a turnover rate of 6.57% and a trading volume of 414,000 shares, amounting to a transaction value of 718 million yuan [1]. Trading Information - On May 23, 2025, the net outflow of main funds for Zhaoyan New Drug was 9.2293 million yuan, while the net inflow from speculative funds was 4.6736 million yuan, and the net inflow from retail investors was 4.5556 million yuan [2]. Company Announcements - Zhaoyan New Drug announced on May 22, 2025, that its member companies subscribed to four structured deposit products from Jiangsu Bank, with a total investment of 440 million yuan. The company confirmed that all other financial products previously subscribed to Jiangsu Bank have been fully redeemed, and these investments are not expected to adversely affect the financial status of the company [1][2]. Structured Deposit Plans - Zhaoyan (Suzhou) New Drug signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 150 million yuan, with an expected annual return rate of 0.1%-2.45%, starting on November 22, 2024, and maturing on May 22, 2025 [3]. - Zhaoyan Management Technology signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 60 million yuan, with an expected annual return rate of 1.60%-2.50%, starting on December 27, 2024, and maturing on December 27, 2025 [3]. - Zhaoyan Management Technology also signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 200 million yuan, with an expected annual return rate of 1.00%-2.56%, starting on February 26, 2025, and maturing on August 26, 2025 [3]. - Additionally, Zhaoyan (Suzhou) New Drug signed a principal-protected floating return structured deposit plan for 30 million yuan, with an expected annual return rate of 1.50% or 2.45%, starting on May 23, 2025, and maturing on November 23, 2025 [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 須予披露交易 進一步認購金融產品 進一步認購金融產品 團 的 財 務 狀 況 造 成 任 何 不 利 影 響。 上市規則的涵義 在 認 購 第 四 項 江 蘇 銀 行 人 民 幣 結 構 性 存 款 產 品 之 前，由 於 根 據 上 市 規 則 第 構 性 存 款 產 品 及 第 三 項 江 蘇 銀 行 人 民 幣 結 構 性 存 款 產 品 計 算（無 論 是 單 獨 計 董 事 會 謹 此 公 佈，於 2025 年 5 月 22 日（交 易 時 間 後），本 集 團 成 員 公 司 剛 認 購 且 於本公告日期仍未到期的該等江蘇 ...